Replay available
Yatharth Hospital and Trauma Care Services (NSE:YATHARTH) Q2 2027 Earnings Call
Yatharth Hospital and Trauma Care Services (NSE:YATHARTH) Q2 2027 earnings call, held 2026-11-04. Watch the replay and read the transcript on 6ix.

- Company
- Yatharth Hospital and Trauma Care Services Limited (NSE:YATHARTH)
- Period
- Q2 2027 earnings call
- Date
- Wed, Nov 4, 2026, 6:07 AM ET
- Replay
- Watch the replay on this page · 59 min
- Results news release
- We hereby submit Press Release for Financial Results for Q2FY27. · Tue, Nov 3, 2026
On 6ix: 6ix.com/event/yatharth-hospital-and-trauma-care-services-limited-yatharth-q2-2027-earnings-call
Replay
Transcript
Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.
0:00 Ladies and gentlemen, good day, and welcome to the Yatharth Hospital and Trauma Care Services Limited Q2 FY 'twenty seven Earnings Conference Call hosted by Elara Securities. I now hand the conference over to Mr. Kashish Thakur from Elara Securities. Thank you, and over to you, sir. Thank you so much,. Good morning, everyone. On behalf of Elara Securities, we welcome you all to q two FY twenty seven earnings conference call of Yatharth Hospital and Trauma Care Services Limited.
0:47 We have with us senior management of the company represented by mister Yadarth Yagi, full time director, mister Amit Kumar Singh, group chief executive officer, mister Nitin Gupta, president finance and group chief operating officer, mister Pankaj Prabhakar, group chief financial officer, Mr. Ashish Kumar Jha, Group Chief Strategy, Mojo and Acquisition Investor Relations and Mr. Suneel Goyal, Group Chief Financial Controller. I now hand over the call to Yatharth's management for the opening remarks. Over to you, Yatharth, sir. Thank you. Good morning, everyone. This is Yatharth, hold time director. Welcome to Yatharth Hospital and Trauma Care Services Limited earning conference call for the quarter and half year ended 09/30/2026.
1:38 Our earnings presentation has been uploaded to the stock exchanges and our website. I hope you have had an opportunity to review it. Well, this is an important moment in Yatharth Hospital's journey. Quarter two f y twenty seven was the strongest quarter to date with revenue growth of 52% year on year and EBITDA growth of 50%. Our existing hospitals at Noida, Greater Noida, Nord Extension and Jhanti Ochha continued to deliver sustained performance with 24% year on year revenue growth. These have been true contributors to our profitability with an EBITDA margin upwards of 28% for these specific hospitals. At the same time, our newer hospitals continue to ramp up, now contributing 28% of group revenue compared to 11% in the corresponding period last year.
2:33 Collectively, these hospitals have moved from an EBITDA loss a year ago to positive EBITDA during h one. Notably, since our listing in August 2023, Yatharth Hospitals has not only more than doubled its capacity from 1,405 beds to about 2,800 beds, but also tripled its revenues and profits. In our earlier communications, we have shared our target to further doubling this capacity in the coming few years. However, the opportunity in health care sector is much, much bigger. Hence, to accelerate our journey grow further, we have entered into a strategic partnership with Advent International for a primary capital investment of 3,150 crore through a preferential issue of equity shares and warrants.
3:26 The transaction is awaiting necessary regulatory approvals, which view this partnership as much as more than just a capital infusion. ADVIN brings over thirty five years of health care investment experience and a significant expertise in building and scaling health care platforms. We believe this combination of long term capital and institutional experience will strengthen our ability to pursue growth opportunities with greater scale and discipline. With Advent as a partner, we now aim to build a larger franchise of 7,000 to 8,000 beds over the next three to five years. We can now move faster and act on larger opportunities while ensuring the same discipline in execution.
4:14 This partnership is also a vote of confidence in what our team has built, a growing network, a proven ability to turn around the hospitals we acquire, and a steady focus on clinical quality. I would like to acknowledge the people behind this progress, our doctors, nurses, management, and all our employees for the commitment, our patients and their families for the trust they place in us and our shareholders for their continued support as we have expanded the network. Against the strategic backdrop, our teams continue to remain focused on clinical excellence. At a cluster in Noida and Faridabad, we are now among the most reputed hospitals of the region.
5:00 At Greater Noida, our teams managed a rare liver condition and reconstructed two nerves in a single sitting for a brachial plexus injury, a procedure very few centers in the region offer. At Paridabad sector twenty, we launched the region's first memory clinic. In recognition of clinical excellence, we have received the hospital excellence and innovation award at the health and wellness excellence awards twenty twenty six for the ASO CHAM organization. And Noida and Greater Noida hospitals ranked among the top in the Noida, Ghazibad region in times of India ranking. We were recognized across multiple specialties in the Outlook best hospital rankings 2026.
5:53 Now shifting to the operating highlights for the quarter. Our ARPU rose 11% year on year to approx 36,000 rupees. Our occupancy stood healthy at 72% on the currently operationalized beds. As we ramp up, about three fifty to 400 beds are yet to be operationalized across Faridabad, Model Town, and Agra, presenting a meaningful headroom for growth. While existing hospitals continue to compound, our newer hospitals are scaling well and contributing more to the network every quarter. Haridabad sector twenty shows what our acquisition and turnaround playbook can deliver. The hospital has turned EBITDA positive in a record period and generated revenue of approximately 40 crores in the last quarter.
6:42 More than 80% of its business comes from cash and private insurance stations with a of approx rupees 40,000. A New Delhi hospital at model town is following the same path. In quarter two, it reported revenue of approximately 26 crore and of around 50,000 rupees, which places it among the premium hospitals and NCR. Alongside Nord Extension, where has also crossed 50,000 rupees. We expect it to break even the Waddle Town Hospital Delhi in the second half of this financial year. Agra, which is our first corporate hospital in that region, has improved steadily since we took it over. In quarter two, the hospital remained EBITDA positive on the revenue of approximately 20 crores.
7:28 Next is Gurugram, our upcoming two fifty bedded hospital in Sector 40, which is progressing well and is expected to operationalize the next financial year. The hospital is expected to serve the premium Gurugram market, giving its location in a highly potential catchment and its proximity to the Delhi Airport with an anticipated ARPOP of above 50,000 rupees. We will continue to evaluate further expansion opportunities with a careful view on strategic fit, quality, and returns. We have a model that has been tested, a network that is delivering growth and profitability, and the resources to scale it further. Our aim is to build a high quality, scaled health care network and to create lasting values for all our shareholders.
8:15 We begin this next phase from a position of strength and with confidence in what lies ahead. Thank you once again for your continued trust and support. I will now hand over to our group CFO, mister who will take you through the financial performances in a greater detail. Thank you, Yatharth, and good morning, everyone. I will take you through the group's financial and operating performance for quarter two and h one f y twenty seven. The group delivered its highest ever quarterly revenue of 4,314 million in quarter two f y twenty seven, representing growth of 52% year on year and 10% sequentially.
9:06 Revenue for h one f y twenty seven stood at 8,241 million, up 52% year on year. This performance reflects the contribution of our established hospitals as well as the increasing scale of our newer facilities. Our existing hospitals,, and contributed 3,109 million in quarter two, registering year on year growth of 24%. In percent volumes across these hospitals increased 28%, while occupancy improved to 78% from 71% a year ago.
10:05 Noida and Jhafi Osha operated at occupancy level above 90%, while Greater Noida reported 78% and Noida extends from 61%. Our newer hospitals at Greater Faridavad, New Delhi, Faridavad Sector 20 and Agra contributed 1,205 million representing 28% of group revenue. Greater Faridavad achieved healthy occupancy of 77%. Ridavad Sector 20, Agra, and New Delhi continue to ramp up their operational census date. Group RPUBs reached an all time high of 36,000, up 11% year on year.
10:59 Noida extension and New Delhi reported an ARPA of approx 50,000. Greater Noida approximately 43,000. Faridavad at 40,000, Noida, 37,000, Greater Faridavad, 35,000, and Agra at 33,000. As some of our newer and premium hospitals are scaling up and the specialty mix continues to improve, we expect our group also to improve meaningfully in the coming years. Talking about margins and profitability. Quarter two EBITDA was a record 1,020 million, increasing 50% year on year and 11% quarter on quarter.
11:55 EBITDA margin improved to 23.6% as the liver hospitals are running profitable. Excluding the ramp up losses at New Delhi and Sarita Watt sector twenty, our adjusted EBITDA margin was healthy at 28%. Profit after that stood at $485,000,000 for quarter two, up 17% year on year and $939,000,000 for h one. However, tax profit, which add back the impact of depreciation to the tax, actually increased 36% year on year. Our operating cash flow during h one, 1,113 million, an increase of 49% year on year.
12:48 As of 09/30/2026, the cash and bank balances stood at 4,289 million, and net debt stood $392,000,000. This provides us with a comfortable balance sheet position as we continue to invest in the network and prepare for the next phase of expansion. To summarize, quarter two and h one f y twenty seven has been marked by a strong revenue growth and improving contributions from our newer hospital. We have also maintained family cap generation and a comfortable leverage position. With the proposed advanced partnership, we believe we are well positioned to pursue the next phase of the growth while remaining focused on education, returns, and quality of care.
13:46 Thank you for your time. I will now hand over the call back to the moderator for question and answer session. Thank you. Thank you very much. We will now begin the question and answer session. Anyone who wishes to ask a question may press star and 1 on the touch tone telephone. If you wish to remove yourself from the question queue, you may press star and 2. Participants are requested to use handset and also to restrict their questions to two First question is from the line of Adyen Chen from Grow Mutual Fund. Congratulations on a great set of numbers. So my first question was, what would be payer mix for this quarter?
14:51 So payer mix for this quarter is close to 34%, which is down, you know, few percent from the last quarter. That's the government institution business. That's the government institution business, and the rest is, you know, equally divided between private insurance and cash business with private insurance having a few percentage more than the cash business. The international business remain close to, you know, around 4% to 5% at the current payment level. So you said 34%. Right? Government mix. And how how much was it last year? 34% is the quarter government mix, and last quarter, it was 37%.
15:39 Okay. Understood. And second question was... Sorry if I missed it in the initial remarks, but what are the what are what are our occupancy levels at Delhi, Faridabad, and Agra? So we have ramped up the kind of occupancy from 68% in the last quarter to 72% in this quarter on a blended level. However, as you've been mentioning about the Moral Town, it has increased to 41% in this quarter. The new hospital at Prithapada has increased to 59%, and the other has been at 58% as of now. Okay. Have that all the all the beds are not operational in these hospitals. So there are beds yet to be opened. Yes. That was my follow-up actually. Since now the occupancies are closer to 60%, any time lines for further opening of the rest of the bed?
16:36 So I think within the next couple of quarters, maybe two to three quarters, we should be opening all the beds. Okay. And just one last question. What would be the share of pharmacy business to our overall revenue in in So, see, there's lots of procedures come with the packages and all. So we don't have that and not look at it in that way as a pharmacy business standing on. Right? But if the questions could be to, you know, give the... Draw some inferences about that, so what is it going on in a government and the court to comment on all these things, I think it's a very premature as of now. That's how being directed. I think the industry is also highly presented. The government is part of it. So let's see how it goes up, but just giving you this thing, I think we don't look at it in that way. The...
17:31 That's what pharmacy percentage. Okay. Understood. I know. Thank you. I'll join back with you for further questions. Thank you. Next question is from the line of Praveen from Fortune Towers Investment. Please go ahead. Hello, sir. Can you hear me? Yes. Good morning. So congratulations on good service numbers. And let's address the elephant in the room. So can you guys comment on, so whatever the implication on your top line and bottom line because of cancer medication capital? That's my first question. And second question is, so any new assets we're planning in this year? And so when can you expect the closure of the ADVANTAIN? Thank you. These are my two questions. Thank you.
18:18 On your first question about the capping on the certain list of cancer drugs, we have did our homework. We have calculated that at the existing list for cancer capping of the margins at 30, the overall impact that it will, you know, have on our EBITDA numbers is around 0.3% reduction because of that specific, you know, pricing on the Onco thing. However, because of the 0.3 reduction due to cancer drugs, our, you know, guidance for the overall company level EBITDA, you know, which is in the coming, you know, quarters and years ahead close to 24%, that remains unchanged. Because this 0.3% reduction in the cancer, we are already, you know, figuring out and coming with strategies to compensate this into other, you know, operational efficiencies and line items and other ways of, you know, composition of this or overall group level EBITDA will not change going forward because of this policy.
19:24 Understood. Thank you. So can you comment on the second question, please? Advance deal? Yeah. I think the admin deal is, you know, at the CCI approvals final stages. I think post Diwali, we can expect it to get the approval this month itself, so we are looking forward for that. Alright. Yeah. Thank you so much, sir. And I wish you all the best, and let more people be treated from your hospitals. Thank you so much. Thank you. Next question is from the line of Shrikant Akolkar from Nuvama. Please go ahead. Just on Advent deals, so just want to know how many tranches will be received this money? Yes. So the the advent money of three one five zero crores will come in two tranches. The first tranche will be $17.50 crores, which will be received after the CCI approval, you know, this month. And the next tranche will be received after fifteen to eighteen months based on certain conditions.
20:32 So in terms of the utilization of funds. Understood. And on the expansion strategy now, because we've got a solid partner as well. So how are we thinking of the expenses in terms of the size of the assets? Maybe potentially our top kind of our top that we may look at, even like this like this specialty, fitness specialty, or maybe standard hospital or chain of hospitals? So what should be our strategy? So our focus remains on multi specialty hospitals. Now we are, of course, looking at much larger deals and we are looking up for a chain of hospitals also. So, I mean, we are looking for hospitals which potentially can have a better our power than us.
21:18 And, you know, we are looking across North India as a priority, and we are also open to other areas that we have have a chain of hospitals available. Also, you know, the assets that, you know, we will continue to acquire from this fund will always be EBITDA positive hospitals. So there will be no absolute drag on the absolute EBITDA because of these acquisitions going forward. Understood. And in terms of the time line, so you have said that in next three to five years, you are to more than double the capacity. And at the same time, we also have our own expansion ongoing and now we've got additional money. So if you can little bit further details on how how many banks will get added next year and maybe if there is a schedule, broad schedule that will really help us.
22:07 So I think we do not have a specific one year or, you know, six month guidance. The the breakup of the, you know, expansion is that on our existing organic plan, you know, we had announced going to 5,000 bed capacity, you know, close to three to, you know, four years going forward. So that remains same. On top of that, around 2,000 to 3,000 beds, we expect to add because of this recent deal, again, in, you know, somewhere in close to four years going forward. Understood. Thank you very much for responding today. Thank you. Thank you. Next question is from the line of from. Please go ahead. Sir, if my... If I may, can you please repeat the ARPOP for each of the hospitals?
23:01 Yeah. Sure. As we said about today, the blended ARPU for this quarter is nearly around 36,000, and we are pleased to share with you that the highest ARPU has been at the node extension hospital nearly around 51,000. Likewise, near... And the daily of around 47,000, proceeding by the Greater Norda of 43,000, borrowed and greater greater Fridabad of 33,000, at 37,000, the new hospital of 37,000, of around 33,000, and is around 14,000. You so So Y o Y growth of the ARPOP is around 11%.
23:53 Right. Thank you so much, sir. Thank you. Next question is from the line of Surin Aran Nayyad from Sunibi Securities. Please go ahead. Hello. Congratulations for the set of numbers. So one question is that now considering the EBITDA to CFO conversion of historically percent. So this quarter, this half, we have seen some kind of softness. So when can we expect the things to improve as the payer mix has improved also compared to last year? So what is the take on that? So,, normally, the EBITDA...
24:39 The con... Collection in the h one is, you know, lower than the full year collection. That's why the... That you would see a slightly dip in the OCF conversion rate. But at the end of the year, we should expect a further 70% conversion. Okay. And secondly you are saying that you are looking for the hospitals, which are actually having ARPU potential higher than us. So in that case, will your standoff increasing to the bed capacity beyond 5,000 will stand given the cash flow of the cash in hand you are ready? Yes. Our existing, you know, plan of 5,000 beds organically in... Within...
25:28 With our internal, know, like, accruals remains as it is. The additional money that we are receiving from Advent, this is more for further expanding the growth, you know, as we have mentioned to buy, you know, about 2,000 plus beds. So these 2,000 beds, you are you are planning in which year? I mean, it it... Is it f '28 or '29 scenario? You see, I mean, you know, the way we're looking at is they... You know, the total bet should... Or close to 2,000 bet should be, you know, talking the combined revenue within next three to four years. However, the acquisition of the... Because we are receiving the first tranche anytime this month, you know, we would like to deploy the first tranche as soon as possible. So maybe, you know, around 40% to 50% of that bet can actually come live from next financial year itself.
26:31 Okay. And can you give some traction? We have some understanding till f twenty eight. But what is... How will be the incremental flows to come so far as the e and l traction from FY '29? Because if you can guide... Because I I understand that there are some some which will be, know, which will be, I mean, related to the kind of hospitals we are going to acquire. So maybe if it is a running hospital, obviously, the CAGR will be improving, and, obviously, there will be not a big data. But if you can give some color from... For FY '29, sir, because, you know, we have clarity till f twenty eight. See, our existing organic plan of, you know, you know, 30% revenue growth, you know, as far as, you know, y y business concern is easily visible for next three to four years on the existing plan before the admin deal. So that will continue on that same trend.
27:35 What we expect is, you know, how we're looking at it, we have not made a, you know, a year or two target. How we look at that is the 3,150 crores that additional we will be deploying to acquire more, you know, assets of, you know, absolute EBITDA and and revenue. So this will be above and beyond that. So, I mean, even if our existing plan of 30% revenue growth in next three point, you know, five years, that is almost around 2.5 x. And if we add the 3,000 but 50 crores of deployment to that, I think easily EBITDA can be added on top of this 2.5 x, which should be easily able to cross us at three x from the current, you know, numbers in next, you know, three point five to four years.
28:22 Okay. Okay. And lastly, from from model model point of view, when the the ramp up will happen, let's say, occupancy will improve to close to 50, 60. Are you facing any kind of competition in that property area? So the Morristown, it's... Yes. That's... There are couple of hospital in there, but we are very clear in our thought process where we are. It's an absolute... A very good, mostly populated area. Right? So very densely populated. We... So far, the growth is very good. I think the next quarter, probably end of the quarter, this would be EBITDA positive. Okay.
29:07 Okay. Thank you. Thank you. Next question is from the line of Khojjan from Nave Money. Please go ahead. Mister, please go ahead with your question. Your line is unmuted. Can you hear me? Yes. Yes. So, sir, my first question is regarding the medical tourism. What is your strategy to increase the contribution of international patient to your overall revenue? What is the international... Which international market are you targeting? And what incentive you are taking to attract more patients, such as partnership with the overseas hospital or international health care agencies.
29:59 Additionally, what are the target are you aiming for over next three to five years? And how could this segment improve your revenue growth and overall profitability? International, let's see, we started focusing on international market last financial year. Right? I think I'm very happy to see the kind of you know, strategy alliances partnership which we did in the various international market. I think it started paying off. So just to give you the perspective that, you know, last year, h two versus this year, h one, we had grown over more than 45% of international business. However, it's still... It's in a a single digit as compared to the top line, but we are making a very significant move. And various areas, like, CIS is contributing. However, it has got affected with the last couple of months because of the war, the other thing. But it's still, I think we are making a very, you know, steady progress in this region. CIS, particularly in African market is contributing very well. Right?
31:02 And lots of... Mean, we have done it. There is a more research, whether it's Ethiopia, South Sudan, another region. So we have a channel partner there. There are couple of, you know, alliances which we've done with the hospitals as well. Right? So we are doing good and as far as contribution is concerned, I think that's the ARPUs always and we all know that the international business contribute a very high ARPU. So I think it's going as per the expected learning next three, four years gonna be fantastic because it's still, you know, no doubt could have not opened for international market. So that is what gonna be a significant addition for us. That's what we are hoping for. And we have a great plan as far as interest is concerned. There is a team working on it. So it's it's quite... It seems very, positive.
31:54 Yeah. Interesting. So next question is regarding the advent interest. So Advent International. So what would be the CapEx for that for the greenfield expansion you are planning? So mostly, we are not planning any major greenfield expansion from the money that we have received from Advent. As we said that we will be acquiring running assets, we will be acquiring, you know, EBITDA positive assets, you know, and and and and the total, you know, bed capacity that, you know, we can look to add from that amount should be close to 2,000 beds in total. Okay. So from 3,000 crores of money, you can additionally acquire 2,000 beds. Yeah? That's right? Roughly around that that month. Yes.
32:43 Thank you. Thank you. Next question is from the line of Akshay Mehta from Seven Rivers Holding. Please go ahead. Hello, sir. Am I audible? Yes. Hi, sir. Congratulations on such a great set of results. I had a few questions on the business. One is, sir, that we we seen that the debt numbers, you know, on a gross level is increasing for you in FY twenty six end and then in H one end as well. I just wanted to understand, you know, where the debt is going and, you know, what is the kind of prepayment that we see over the year? So I think as far as the total, you know, debt is concerned, the the addition to the debt from the last financial year has been, you know, primarily for a...
33:38 You know, the 100 crores that we have spent on the Gurugram facility. Plus, you know, around 100 crore more has been taken for certain, you know, medical equipments that will be... And that have been added to both the model town hospital, the sector hospital, as well as certain, you know, construction that is already happening at a full swing in the Gurugram hospital. But, you know, we feel that this is the peak level of debt for us, at least for next, you know, a few, you know, quarters to come. Debt will definitely... Eventually could go down also from here. Even, you know, we feel that, you know, going forward, you know, even though the full focus is on the acquiring new hospitals with the admin money, but if the the the acquisitions are taking time as far as certain assets are concerned, we can also, you know, briefly look to certain...
34:36 At a minute level, reduce debt from that amount also from a small amount. So I think this is the peak level of debt that the company is expecting in the coming quarters. Okay. Okay. My next question, sir, you know, have a hospital. So what's happening there? So in one quarter, you've seen the, you know, occupancy go down sharply, but then your outcome is also gone up. Are we seeing a a big mix change... Case mix changes in that happening? So I think, you know, as far as Agri is concerned, we are very happy with the numbers and the way that hospital has, you know, ramped up and scaled well. We have become the most preferred hospital in that area, and I can also say that the number of robotic surgeries that we are doing in Aggar is probably, you know, at par or even higher than certain, you know, NCR hospitals.
35:23 Definitely, you know, the Agra is is on a similar monthly trend now as to what it was in quarter one as well as well as earlier months of, you know, quarter two. So I think going forward, we are all not just optimizing, you know, pay mix there, but we are in the line to, you know, renovate the facility as well as add certain more beds, and certain floors are also in the renovation stage there. In terms of, you know, the case mix or the treatments, any any new additions have been done or, you know, anything that you're planning to add in Agra? So, you know, it's absolutely... We recently added a CTVA surgery and cardiac surgery. We recently...
36:08 We are planning to add, you know, pediatric cardiac as well. Right? We are also strengthening couple of the, you know, personalities which we feel that was not tied up to the mark. So then that's happening, and I I just said it that it's... I mean, the work is happening there. So, I mean, in a way, largely, we are doing everything except you said that... I mean, the radiation on point in the transplant program. But Agora is doing good. Yes. There are few changes gonna happen depends on how the, you know, the specialties or the department, you know, perform in the future. Okay. And, sir, the last question, sir, what's happening on the IT matter, sir? You've seen the demand notice after that. What what has happened? And what is the forward plan?
36:54 So I think as we said that the IT matter, you know, has been resolved, you know, and then we have received the final demand. Okay. So, you know, as far as, you know, we were saying that the final demand has come and the matter is resolved now. There has been no... You know, earlier also, all the assets and, you know, the FDs were leased for the company. As far as even, you know, going forward is concerned, because even the existing demand can be feel can significantly reduce. That is what... You know, that is the only reason why we feel that, you know... And because of taking legal opinions and even with the talks from the department itself, we have been advised to, you know, going to appeal against that. However, it is a normal course of appeal. It is not that that, you know, the whole matter is still pending at a larger scale. The capping has been done as far as the demand is concerned, and we also feel that this will significantly reduce.
37:53 So that's what we are doing, and, you know, we expect this also to, you know, reduce in the coming quarters ahead. Okay, sir. Thank you, and congratulations once again. Thank you. Next question is from the line of Meet Mehta from Integrity Ventures and Partnerships. Congratulations on great set of results. So my first question is on the Onco status of the model town and the Faridabad hospitals. When we are expecting the oncology segment to go live in both of the hospitals? I think everything is done now.
38:39 The equipment is already been installed. Now it's in some form that is with the ER. We typically forty, forty five days. So we are in the last leg of this thing. The... I mean, the the the the clinical manpower has already been, you know, on rule. Right? So probably, you'll think that the next forty five to sixty days, the the entire spectrum of the implanting, medical and surgical already we're doing it. So the radiation, the nuclear, we're gonna start in next two months. So this is Sector 20. Moral town is gonna take time. I think that's still in a growing phase as of now because you have to compete. You have to start, you know, new setup for this entire, you know, radiation thing, the bunkers and all because in fact, there were... It was already there. Here, we need to, you know, start it. So they wanna planning phase. I think they already...
39:34 The drawing and already the the drawing already in come. So we'll be working out, but as you know that Delhi has got a gap to now, the concessions are on hold. So probably it will take two, three months. We'll take to start our work, so another six months, need to. Even... However, we've already started medical and surgical oncology model down. And recently, have hired a certain star doctors as far as oncology for those specialties is concerned, and we have already started seeing good numbers. You know, as Amit mentioned that we will be adding radiation oncology in that hospital. I think the time line should be somewhere around, you know, close to eight to nine months. Got it. And are we on track to breakeven on the Delhi Hospital?
40:23 Say that to the next quarter, I think we should be. So it's very much Delhi is doing as per the expected line. Right? So next quarter, I think Delhi should be back to them. So if you see Yeah. So losses losses of losses of more town has been reduced quarter on quarter. For q one, losses was 55,000,000. This quarter, we reported losses of 38,000,000. Okay? So next quarter, we are very much sure in the month of December. December is a breakeven month for the Delhi quarter... For Delhi Hospital. Got it. Got it. And last on the, you know, bed addition, anything on the Noida, Greater Faridabad Hospital and the Jhansi Hospital? Because we are reaching to, you know, optimum utilization of the capacity.
41:08 So any color on those three facilities? So, you know, there's not much scope for expansion in those three hospitals. You know? However, you know, we are looking to improve marginally in terms of the ARPOP and the payer mix is concerned in those hospitals, but there's no specific plans for any bronchie capacity expansion in those hospitals. Sure. Any any new hospitals that we are looking in those geography? As we said that we are targeting a huge capacity addition in terms of, you know, new hospitals and new beds. So we are, you know, focusing across, you know, the areas of NCR, micro markets of NCR where we are still not present. And at a larger scale within the whole North India market, you know, I mean, especially, we still see UP, Riyana, Punjab, and, of course, Delhi NCR has, you know, good good scope for growth. And as I said, now along with the admin deal, you know, we have expanded our horizon. The priority still remains North, but if there's a good cluster of hospitals available outside North, we will be actively looking to evaluate that.
42:18 Yeah. Sure. Sure. Yatharth, congratulations on the great set of results, and all the best for the coming future. Thank you. Next question is from the line of from GROW Mutual Fund. Please go ahead. Yeah. Hi. Thank you for the follow-up. So my first question was, is there any change in our 24% plus margin guidance for the year given that both our new assets actually see... Assets are seeing faster ramp up? I think the the the guidance remains same. In fact, you know, we also have to cover up the difference from the oncology pricing differences, but we remain sure that the guidance we have for the EBITDA margins will continue to be same.
43:06 Okay. And with Gurugram coming up next year and also the admin funds being deployed most next year, should we expect the margins to be kind of flat over the next couple of years from FY twenty seven level? I think, you know, we have not made a blended margin plan because, you know, that will depend upon the the the the type of assets and the type of deals we're able to close from the first chance we get. However, you know, what we are we are forecasting is our existing or, you know, plan, where the EBITDA margins, you know, will will continue to be, you know, on a on a on a rising trend, but they will not you know, they will be upwards of 24% for the upcoming years. And then then and then... And the blended margins from the new hospitals will depend on the type of deals we're able to close. And just remember that that the existing hospital, particularly the Faridabad and Delhi will start contributing to whatever the drag would be.
44:09 Okay. Fair enough. And one last question. How soon do we expect our Gurugaam facility to breakeven given that it's a competitive market? I think, Gurugram, we are also targeting to breakeven in fifteen to fifteen months. But, you know, it will be a very high premium ARPA facility with, you know, very high pay mix of cash and private insurance as well as international patients. As far as banking is concerned, I think 15 would be right on the conservative side. Okay. Thank you. Those are my questions. Next question is from the line of Akshayashunde from Centrum Broking. Please go ahead with your question. Your line is unmuted.
45:10 May be requested to please unmute yourself and proceed ahead with your questions. As there is no response, we'll move to the next question, which is from the line of Praveen from Fortune Tower Investments. Go ahead. Yes. So thank you for the follow-up question. Sir, my question is on your next leg of expansion. So what kind of assets will you be more interested in? Will you be interested in acquiring more of a operational effect, or you want to follow this, you know, operation and maintenance asset light model? And if you're planning for both, can you can you help us, you know, what would be the kind of a breakup there, please? Thank you. Yeah. I think because it would be a mix of both, primarily, they would be 100% equity owned assets because, you know, with a large capital, we have to deploy now or we can look at larger, you know, chain of hospitals that we can deploy. There are few chain of hospitals that are available within the North market itself that we are carefully and and, you know, evaluating.
46:06 And those are mostly, you know, asset owned... A 100% equity owned chain of assets. So I think, yes, going forward, we can even look to have, you know, certain hospitals which are available in O and M, but they would be mostly stand alone hospitals, which would be mostly part of our initially 5,000 bed capacity expansion is concerned. But from the new advent capital, it would mostly be, you know, a fully owned assets. Yeah. Thank you. Thank you for the answers. Thank you. Next question is from the line of Prashant Sharma from Hemp Securities. Please go ahead. Hello. Good morning, everyone. Sir, as you mentioned in the previous call to bring down the government business to... From 35% to 20%.
46:57 And, sir, by keeping the government business in certain days, like, percent in the new... Newer hospitals. So, sir, are we following that trend in the newer hospitals, and what would be the outlook going forward for the government business in the next two two two to three years, sir? So, you know, the new hospitals, as you can already see from the performance of model town and Sector 20 Faridabad, and even the, you know, Greater Faridabad, which was the newest before them. You know, the government business in the two new hospitals is not more than, you know, 15 to 20%. So we're actually, you know, not following that playbook only, but also, you know, showing the results of that. And as the scale of these hospitals ramp up, that will significantly help us to, you know, reach that initial government business target is concerned. And even Gurugram would be on a similar line next year when it starts. So I think we are very much following that trend, and the the the guidance on that remains similar.
47:54 Okay, sir. Thank you. That's all from my side, sir. And all the very best, sir. Thank you. Next question is from the line of Akshay Shandeep from Centrum Broking. Please go ahead. Akshay Shunde, please go ahead with your question. Your line is unmuted. May be requested to please unmute yourself and proceed ahead with your questions. As there is no response, we'll move to the next question, which is from the line of Rishikesh Poy from Purnata Investment Advisory. I just have one question around the oncology share.
48:46 So include cognitive data, Yatharth has recently launched a comprehensive cancer care center. Are you seeing any pressure from these oncology patients who fall on returning oncology time there? I think the full scale of oncology, if you say, I think the... Except the one hospital, which has a more of the, you know, medical college, I think I don't think so any other, you know, hospital has got, which has got a couple of hospital as well as fully spectrum of, you know, onco is concerned. And what is your second question? I missed that. Second part of it. Okay. Okay. Okay.
49:34 So the next update I want, what is the current status for Guruvaram Sector 40 facility in terms of construction? So a construction... Yeah. So we have kind of... We are on the revamping the existing building, and we are kind of adding more capacity there. We have submitted the plans also, and we have started, you know, modifying the existing building according to the plan. And as soon as we get the plan approval, we will start the construction on this and remain part of the meeting. And this facility is being, you know, created on a very premium end. You know, we, you know, gone for one of the largest room sizes across the program, you know, market other hospitals have. So I think we are eagerly awaiting for the full launch of this facility.
50:34 Okay. Okay. And I just want to add my first question. I think you missed the system. So for that one, I don't see any pressure from the oncology patient who fall or in the retaining oncology talent in the greater for oncology in the. No. So Greater Noida, you know, we have two hospitals technically with Greater Noida and even Nord Extension. The Nord Extension is technically with North West also. So, you know, we both... At that, you know, facilities are getting the highest number of oncology patients as far as any other hospital is concerned in greater order. So I think we do not see any impact. In fact, if you look at it, our absolute volume of oncology business has increased in both these hospitals. We are, you know, adding more doctors also in terms of leading doctors of NCR. We are planning to add in these two hospitals as far as oncology is concerned.
51:32 So so far, there's no impact in terms of the volume. Okay. And in terms of talent? So I think that we have enough pool of the doctors. Right? So we've got eight hospitals, and I have enough pools of patients. That will pools of doctors. And then if you see the more and more hospitals coming up in that particular region, it's also, you know, attract clinical talents. So I think that's not gonna be a... I think clinical... That is not there in that particular market, and we're very confident that we're even... They don't know that when we have our entire spectrum, which is very soon we wanna add a, you know, the nuclear as well as radiation oncology. And they don't have a certificate. So the doctor's level, I don't think there will be any challenge.
52:21 Okay. Got it. Thanks. Thank you. Next question is from the line of Kashish Thakur from Malara Securities. Please go ahead. Hi, sir. Thank you for the opportunity. One question. Sir, how are we pursuing the Supreme Court's judgment probably that along with Onco, we should be having a capping on other drugs as well. That will probably erode much of our profitability and also just wanted to get some view from your end on that aspect. No. As I said in my early commentary, so it is still nothing has come up. Is there discussions going on? So the matter is in a... In... Before the course, so we don't want to comment as such. But, yes, instead that hospital industries has already made their representations, and there is some going on. What will happen? We don't know. But I think that's...
53:20 Whatever will happen is it will be for the best standing industry and government will definitely be in any discussions and we have made our representations. So nothing much comments on it, but what... Whenever it will happen, we'll see accordingly, and then we'll plan. See, we have always, you know, as a organizations, try to, you know, restructure and evolve our strategy according to regulatory policies and new framework. Just like in oncology, you know, yes, there was a marginal and a small impact for us, but that involves... It was not high. But even then, you know, we have already, you know, worked out on certain other line items and operational efficiencies so that our EBITDA target guidance doesn't change. So I think any regulatory policy changes going forward, you know, maybe in the pharma or any other aspect, I think, you know, we would be looking to, you know, evolve our strategies and and work, you know, still trying to meet the guidance that we have for the next few years.
54:20 That was very helpful. Thank you so much. Thank you. Next question is from the line of from Integrity Ventures and Partnerships. Please go ahead. Yes. Thanks for the follow-up. Just wanted to get a sense on the CapEx per bed. So historically, we have acquired assets which were. So if you can give some color on the CapEx per per bit that we are looking for the next phase of expansion with the admin money coming in. So any sense on that, please? That would be helpful. So I think because of... Specifically from the admin money, we are not, you know, creating any, you know, greenfield assets, and we might not be going for, you know, absolute stress assets.
55:08 We would be going for assets. You know, yes, there would be huge upside in potential for them. It would not be hospitals. But they... You know, we are seeing more of a... You know, in terms of the total, you know, bit capacity as far as the... And the absolute EBITDA that we can add. And with the options that, you know, we have few evaluated and certain more options can come going forward, you know, we feel that, you know, close to 2,000 beds can be added, but it shouldn't be looked at purely CapEx per bed just on the bed angle because these 2,000 beds would be significantly contributing to the top line and the EBITDA. So I think that... That's where the real value will come and not just from the bed edition of these further expansion.
55:57 Yeah. Yeah. That was helpful, and thank you. Thank you. Next question is from the line of from. Please go ahead. Hello, sir. Am I audible? It's here. Hello? Am I audible? Yes. You may please go ahead. Yeah. So let's, like, given your preference for acquiring large size and EBITDA positive hospitals, what kind of percent and valuation multiples are you currently targeting? And second one, how do you evaluate paying a premium for hospitals with the higher growth potential? See, think it's very difficult to put a number to what multiple, you know, the deals will happen.
56:46 For us, the way we look at this, you know, if a hospital has a good upside of potential of where it is and, you know, if we can really expand, only the... You know, that is the biggest criteria. And, you know, for that also premium really depends upon the percentage of, you know, the growth that the hospital is possible. Also, factor that we can also consider in terms of a case of a premium given to a valuation, if that hospital's average revenue per occupied bed is higher than our group average or if the payments of that hospital or a chain of hospital has more cash in private insurance mix than even our existing platform. So that also becomes another criteria for us to consider a premium as well as the deals are concerned. Okay, sir. Thank you.
57:38 You. Next question is from the line of, an individual investor. Please go ahead. Mister, please go ahead with your question. Your line is unmuted. Mister, may we request you to please proceed ahead with your question? Your line is unmuted. There is no response from the participants. And as there are no further questions from the participants, I now hand the conference over to management for closing comments. So thank you, everyone, for this h one presentation. So looking forward for the next quarter result and meeting soon. Thank you. Thank you, everyone.
58:26 Thank you. On behalf of Alara Securities, that concludes this conference. Thank you for joining us, and you may now disconnect your lines. Thank you.
Latest news releases
- NSE:YATHARTH — We hereby submit Press Release for Financial Results for Q2FY27. · Tue, Nov 3, 2026
- NSE:YATHARTH — Yatharth Hospital And Trauma Care Services Limited Press Release Sep 17 2026 · Thu, Sep 17, 2026